Cleveland HeartLab Adds Another Patent!

Cleveland HeartLab (CHL), the premier cardiovascular disease (CVD) management company, recently announced that a new patent for Myeloperoxidase (MPO) testing has been issued. CHL is the exclusive license holder for MPO testing, which is covered by a number of patents including this newly issued patent. Originally discovered and developed at the Cleveland Clinic, MPO testing has been recognized in over 100 peer-reviewed publications as a key measure of vascular inflammation. This new patent will add to the company’s already existing portfolio of intellectual property rights, which include 24 issued patents and an additional 17 pending patent applications. “This latest patent increases our intellectual property portfolio and further demonstrates CHL’s leadership in bringing valuable and innovative tests to market,” said Jake Orville, President and CEO.

According to the U.S. Department of Health and Human Services, Americans suffer 1.5 million heart attacks and strokes each year. CVD—including heart disease and stroke—is the leading cause of death in the U.S. Every day, 2,200 people die from CVD—that’s nearly 800,000 Americans each year, or 1 in every 3 deaths. According to the American Heart Association, half of those who suffer heart attacks and strokes have “normal” cholesterol levels, so tools such as MPO testing are desperately needed to improve our ability to assess CVD risk in patients whose risk is not revealed by cholesterol testing alone. The U.S. spends approximately $4 trillion on healthcare annually, one-sixth of which is spent treating CVD, according to the Centers for Disease Control and Prevention. A recent publication in the Journal of Medical Economics demonstrated the use of MPO testing in combination with standard lipid testing could reduce heart attacks and strokes by approximately 10% compared to traditional cholesterol testing alone, not only saving lives but also hundreds of millions of healthcare dollars.